Kevin D. Rynearson

Kevin D. Rynearson

Auto-generated profile, based on publicly available information

Kevin D. Rynearson

Department of Neurosciences University of California, San Diego La Jolla California USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KRKevin D. Rynearson
Kevin D. Rynearson
MPMoorthi Ponnusamy
Moorthi Ponnusamy
OPOlga Prikhodko
Olga Prikhodko
YXYuhuan Xie
Yuhuan Xie
Can ZhangCan Zhang
Can Zhang
SWSteven L. Wagner
Steven L. Wagner
A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer’s disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allosterically modulate γ-secretase, reducing the net production of Aβ42 and to a lesser extent Aβ40, while concomitantly augmenting production of Aβ38 and Aβ37. This GSM demonstrated robust time- and dose-dependent efficacy in acute, subchronic, and chronic studies across multiple species, including primary and secondary prevention studies in a transgenic mouse model. The GSM displayed a >40-fold safety margin in rats based on a comparison of the systemic exposure (AUC) at the no observed adverse effect level (NOAEL) to the 50% effective AUC or AUCeffective, the systemic exposure required for reducing levels of Aβ42 in rat brain by 50%.

27 January 2022 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
ACAndrew B. Caldwell
Andrew B. Caldwell
QLQing Liu
Qing Liu
Can ZhangCan Zhang
Can Zhang
GSGary P. Schroth
Gary P. Schroth
DGDouglas R. Galasko
Douglas R. Galasko
SSShankar Subramaniam
Shankar Subramaniam
While amyloid‐β (Aβ) plaques are considered a hallmark of Alzheimer's disease, clinical trials focused on targeting gamma secretase, an enzyme involved in aberrant Aβ peptide production, have not led to amelioration of AD symptoms or synaptic dysregulation. Screening strategies based on mechanistic, multi‐omics approaches that go beyond pathological readouts can aid in the evaluation of therapeutics. Using early‐onset Alzheimer's (EOFAD) disease patient lineage PSEN1A246E iPSC‐derived neurons, we performed RNA‐seq to characterize AD‐associated endotypes, which are in turn used as a screening evaluation metric for two gamma secretase drugs, the inhibitor Semagacestat and the modulator BPN‐15606. We demonstrate that drug treatment partially restores the neuronal state while concomitantly inhibiting cell cycle re‐entry and dedifferentiation endotypes to different degrees depending on the mechanism of gamma secretase engagement. Our endotype‐centric screening approach offers a new paradigm by which candidate AD therapeutics can be evaluated for their overall ability to reverse disease endotypes.

1 September 2020 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
KRKevin D. Rynearson
Kevin D. Rynearson
RBRonald N. Buckle
Ronald N. Buckle
RHR. Jason Herr
R. Jason Herr
NMNicholas J. Mayhew
Nicholas J. Mayhew
XCXinchao Chen
Xinchao Chen
SWSteven L. Wagner
Steven L. Wagner